Get the Stockscreener App
52.73
5.45%
2.725
Terns Pharmaceuticals Inc stock is traded at $52.73, with a volume of 61.46M.
It is up +5.45% in the last 24 hours and up +27.42% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$50.00
Open:
$52.63
24h Volume:
61.46M
Relative Volume:
19.93
Market Cap:
$5.74B
Revenue:
-
Net Income/Loss:
$-94.44M
P/E Ratio:
-51.09
EPS:
-1.032
Net Cash Flow:
$-77.99M
1W Performance:
+10.35%
1M Performance:
+27.42%
6M Performance:
+608.67%
1Y Performance:
+1,488%
1-Day Range:
$52.59
$52.79
1-Week Range:
$46.75
$52.79
52-Week Range:
$1.865
$52.79
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
52.73 | 5.44B | 0 | -94.44M | -77.99M | -1.032 |
VRTX
Vertex Pharmaceuticals Inc
|
457.90 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
752.46 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
324.52 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
694.18 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.20 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Leerink Partners | Outperform |
| Nov-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-03-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Resumed | H.C. Wainwright | Neutral |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Unsurging Financial Prospects for Terns Pharmaceuticals Inc. - timothysykes.com
Shareholder Alert: The Ademi Firm investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire
Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires - WRAL
MRK: Acquisition brings TERN-701, a high-potential CML therapy, into the hematology portfolio - TradingView
Merck to Acquire HBM Portfolio Company Terns Pharmaceuticals for USD 6.7 Billion - marketscreener.com
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms - BioSpace
Merck makes bold $5.7 billion bet on Terns Pharmaceuticals - Rolling Out
Why Merck's $6.7 Billion Deal Could Start A Fight - Investor's Business Daily
Merck acquires Terns Pharmaceuticals stock for $6.7 billion - Investing.com
Merck to acquire Terns Pharmaceuticals in US$6.7 bil deal - The Edge Singapore
Merck to buy Terns Pharmaceuticals for $6.7bn - Sharecast.com
Merck (MRK.US) Plans to Acquire Biotech Firm Terns Pharmaceuticals (TERN.US) for USD6.7 Billion - AASTOCKS.com
MSD buys biotech Terns Pharmaceuticals for nearly USD 6bn - medwatch.com
Merck to Acquire Terns Pharmaceuticals in $6.7 Billion Deal - marketscreener.com
Merck (MRK) to Acquire Terns Pharmaceuticals for $6.7 Billion - GuruFocus
Merck (MRK) to Acquire Terns Pharmaceuticals (TERN) for $6.7 Bil - GuruFocus
Terns Pharmaceuticals to Be Acquired by Merck - TipRanks
Merck Seals $6.7B Deal to Acquire Terns Pharmaceuticals and Boosts Oncology Pipeline - StockInvest.us
Q&A: Why Is Merck Spending Nearly $6 Billion to Acquire Terns Pharmaceuticals? - citybiz
Merck (MRK) Seals $6.7B Deal for Terns Pharma (TERN) in Latest Cancer Portfolio Expansion - Blockonomi
Merck to Launch Tender Offer for Terns Pharmaceuticals (NASDAQ: TERN) - Stock Titan
Merck (MRK) to Acquire Terns Pharmaceuticals in $6.7 Billion Dea - GuruFocus
Merck (MRK) Announces Acquisition of Terns Pharmaceuticals - GuruFocus
Terns Pharmaceuticals to Be Acquired by Merck in $53-Per-Share Tender Offer and Merger - TradingView
Merck (MRK) Stock Acquires Terns Pharma (TERN) for $6.7 Billion to Bolster Cancer Pipeline - CoinCentral
Merck to buy Terns Pharmaceuticals (NASDAQ: TERN) in $6.7B cash deal - Stock Titan
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline - CNBC
Merck To Acquire Terns In $6.7 Billion Deal – Signaling Fresh Push In Competitive Cancer Drug Race - Stocktwits
The merger and acquisition deal between Merck and Terns Pharmaceuticals, Inc. has received official approval from the boards of directors of both parties. - Bitget
Merck to acquire Terns Pharmaceuticals for $53 per share in cash - MSN
Merck to buy Terns for $6.7 billion - breakingthenews.net
Merck Close to $6 Billion Deal to Acquire Terns Pharma, FT Says - Meyka
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) - Bitget
Merck to buy oncology firm Terns Pharmaceuticals in $6.7 billion deal - Investing.com Australia
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) - Benzinga
Merck (MRK) Nears Acquisition Deal with Terns Pharmaceuticals - GuruFocus
MSD rumoured to be nearing $6bn play for Terns Pharma - pharmaphorum
Merck Nears $6 Billion Deal To Buy Terns Pharma: Report - Benzinga
MSD close to USD 6bn acquisition of Terns Pharmaceuticals - medwatch.com
Merck Nears Deal to Buy Terns Pharmaceuticals - Bloomberg
Why Terns Pharmaceuticals Stock Is Suddenly Sinking - TipRanks
Merck Nears $6 Billion Deal to Acquire Terns Pharma - marketscreener.com
SLS Vs. TERN: Which Pharma Stock Has More Upside As Merck Eyes $6B Cancer Bet Ahead Of Keytruda Patent Cliff - Stocktwits
Merck nears $6 bln deal for Terns Pharma, FT reports By Investing.com - Investing.com Canada
Merck (MRK) Nears $6 Billion Acquisition of Terns Pharmaceuticals (TERN) - GuruFocus
Terns Pharma shares surge on reported $6B acquisition talks with Merck (MRK:NYSE) - Seeking Alpha
Merck nears $6 bln deal for Terns Pharma, FT reports - Investing.com
Merck’s Strategic Move with Terns Pharma: A Bold Oncology Investment in a Competitive Market - Bitget
Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports - marketscreener.com
According to insiders, merger negotiations between Merck (MRK) and Terns Pharmaceuticals, Inc. (TERN) have entered a critical stage. - Bitget
Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports - marketscreener.com
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):